Meeting
2017 ASCO Annual Meeting
A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Authors
Robin Kate Kelley
University of California, San Francisco, San Francisco, CA
Robin Kate Kelley , Edward Gane , Eric Assenat , Jurgen Siebler , Peter R. Galle , Philippe Merle , Isabelle Ollivier-Hourmand , Ann Cleverly , Ivelina Gueorguieva , Michael M. F. Lahn , Sandrine J. Faivre , Karim A. Benhadji , Gianluigi Giannelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Other GI Cancer
Clinical Trial Registration Number
NCT01246986
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4097)
DOI
10.1200/JCO.2017.35.15_suppl.4097
Abstract #
4097
Poster Bd #
89
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.
First Author: Andrew X. Zhu
Poster
2014 ASCO Annual Meeting
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
First Author: Mairead Geraldine McNamara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
First Author: Mingyue Cai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon